Masanari Kuwabara1, Koichiro Niwa2, Shuzo Nishihara2, Yutaro Nishi2, Osamu Takahashi3, Kazuomi Kario4, Kazuhiro Yamamoto5, Takeshi Yamashita6, Ichiro Hisatome7. 1. Department of Cardiology, St. Luke's International Hospital, Tokyo, Japan; Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Sciences, Yonago, Japan; Department of Cardiology, Toranomon Hospital, Tokyo, Japan. Electronic address: kuwamasa728@gmail.com. 2. Department of Cardiology, St. Luke's International Hospital, Tokyo, Japan. 3. Center for Clinical Epidemiology, St. Luke's International University, Tokyo, Japan. 4. Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan. 5. Division of Cardiovascular Medicine, Endocrinology and Metabolism, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan. 6. The Cardiovascular Institute, Tokyo, Japan. 7. Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Sciences, Yonago, Japan.
Abstract
BACKGROUNDS: The relationship between serum uric acid (SUA) and atrial fibrillation (AF) remains unclear because many parameters and diseases influence AF. This study was conducted to clarify the role of hyperuricemia as an independent competing risk factor for AF in an apparently healthy general population. METHODS: We retrospectively analyzed the medical records of 90,143 Japanese subjects who underwent annual regular health check-up in St. Luke's International Hospital, Tokyo, between January 2004 and June 2010. Of those subjects, 291 (0.32%) were identified as having AF by 12 leads electrocardiography. First, we analyzed 90,117 subjects to clarify the independent competing risk factors for AF and obtained odds ratios (ORs) by logistic regression analysis. Second, we excluded 40,825 subjects with hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, and current medication for hyperuricemia and/or gout, and we analyzed 49,292 subjects. RESULTS: First, AF groups were significantly higher SUA level (OR: 1.35; 95% confidence interval (CI), 1.22-1.50) than non-AF group. OR of hyperuricemia (>7.0mg/dL of SUA) for AF was 2.75 (95% CI, 2.10-3.60). Second, after multiple adjustments, higher SUA level (OR: 1.53; 95% CI, 1.21-1.92) was a significantly independent competing risk factor for AF, as well as older age, male sex, higher body mass index, lower FEV1/FVC, and higher hemoglobin. OR of hyperuricemia for AF was 3.19 (95% CI, 1.81-5.62). CONCLUSIONS: Hyperuricemia is an independent competing risk factor for AF. Further prospective intervention studies are needed to prove whether lowering SUA level might be important for preventing AF or not.
BACKGROUNDS: The relationship between serum uric acid (SUA) and atrial fibrillation (AF) remains unclear because many parameters and diseases influence AF. This study was conducted to clarify the role of hyperuricemia as an independent competing risk factor for AF in an apparently healthy general population. METHODS: We retrospectively analyzed the medical records of 90,143 Japanese subjects who underwent annual regular health check-up in St. Luke's International Hospital, Tokyo, between January 2004 and June 2010. Of those subjects, 291 (0.32%) were identified as having AF by 12 leads electrocardiography. First, we analyzed 90,117 subjects to clarify the independent competing risk factors for AF and obtained odds ratios (ORs) by logistic regression analysis. Second, we excluded 40,825 subjects with hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, and current medication for hyperuricemia and/or gout, and we analyzed 49,292 subjects. RESULTS: First, AF groups were significantly higher SUA level (OR: 1.35; 95% confidence interval (CI), 1.22-1.50) than non-AF group. OR of hyperuricemia (>7.0mg/dL of SUA) for AF was 2.75 (95% CI, 2.10-3.60). Second, after multiple adjustments, higher SUA level (OR: 1.53; 95% CI, 1.21-1.92) was a significantly independent competing risk factor for AF, as well as older age, male sex, higher body mass index, lower FEV1/FVC, and higher hemoglobin. OR of hyperuricemia for AF was 3.19 (95% CI, 1.81-5.62). CONCLUSIONS:Hyperuricemia is an independent competing risk factor for AF. Further prospective intervention studies are needed to prove whether lowering SUA level might be important for preventing AF or not.
Authors: A Mantovani; R Rigolon; A Civettini; B Bolzan; G Morani; S Bonapace; C Dugo; G Zoppini; E Bonora; G Targher Journal: J Endocrinol Invest Date: 2017-07-15 Impact factor: 4.256
Authors: Masanari Kuwabara; Petter Bjornstad; Ichiro Hisatome; Koichiro Niwa; Carlos A Roncal-Jimenez; Ana Andres-Hernando; Thomas Jensen; Tamara Milagres; Yuka Sato; Gabriela Garcia; Minoru Ohno; Miguel A Lanaspa; Richard J Johnson Journal: Am J Nephrol Date: 2017-03-11 Impact factor: 3.754
Authors: Masanari Kuwabara; Remi Kuwabara; Ichiro Hisatome; Koichiro Niwa; Carlos A Roncal-Jimenez; Petter Bjornstad; Ana Andres-Hernando; Yuka Sato; Thomas Jensen; Gabriela Garcia; Minoru Ohno; James O Hill; Miguel A Lanaspa; Richard J Johnson Journal: Obesity (Silver Spring) Date: 2017-09-18 Impact factor: 5.002
Authors: Masanari Kuwabara; Koichiro Niwa; Ichiro Hisatome; Takahiko Nakagawa; Carlos A Roncal-Jimenez; Ana Andres-Hernando; Petter Bjornstad; Thomas Jensen; Yuka Sato; Tamara Milagres; Gabriela Garcia; Minoru Ohno; Miguel A Lanaspa; Richard J Johnson Journal: Hypertension Date: 2017-04-10 Impact factor: 10.190